- Glioblastoma multiforme (brain cancer)
- Persistent, recurrent, or metastatic breast cancer
- Metastatic cervical cancer
- Advanced kidney cancer
- Metastatic colorectal cancer
- Advanced non-small-cell lung cancer
- Liver Cancer- Hepatocellular carcinoma
- Cancers of the ovary, cervical, fallopian tube, or primary peritoneal cancer


BEVAREST 100MG
MRP | : |
|
Price | : | ₹7,300.00 |
You Save | : | ₹8,670.00 (54.29%) |
1 Vial 4 ml Injection
Bevarest-100 Injection 4 ml is a monoclonal antibody utilized for the treatment of metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, as well as colon and rectal cancer. Cancer is characterized by the uncontrolled growth and reproduction of cells in a specific area of the body. It can originate in one part and subsequently spread to others, a process known as metastasis.
Bevarest-100 Injection 4 ml contains ‘Bevacizumab’, which targets vascular endothelial growth factor (VEGF) present on the lining of lymphatic and blood vessels. VEGF promotes the growth of blood vessels within tumors, supplying them with oxygen and nutrients. By inhibiting vascular endothelial growth factor, the flow of oxygen and nutrients to the tumor is restricted, leading to its reduction or halting its growth. Therefore, it plays a crucial role in cancer treatment.
Bevarest-100 Injection 4 ml should be administered by a healthcare professional; self-administration is not advised. Your doctor will determine the appropriate dosage and duration based on your medical condition. In certain instances, Bevarest-100 Injection 4 ml may lead to side effects such as loss of appetite, constipation, fever, nosebleeds, and alterations in speech and taste. Most of these side effects are temporary and do not necessitate medical intervention. However, if they persist or worsen, it is important to consult your doctor.
Avoid using Bevarest-100 Injection 4 ml if you are pregnant. It is essential to employ effective contraception during treatment and for six months following the final dose. This injection may induce drowsiness and fainting; therefore, refrain from driving while undergoing treatment with Bevarest-100 Injection 4 ml. Additionally, do not breastfeed during treatment and for six months after the last dose of Bevarest-100 Injection 4 ml. Keep your healthcare provider updated about your health status and all medications you are taking to prevent any potential side effects.